Poster Sessions
- 17Ex vivo generation of highly purified and activated natural killer cells from human peripheral blood in accordance with GMP/GCTP for clinical studies
- 3775T4 oncofoetal protein – an old antigen for a novel prostate cancer vaccine
- 387A CD122-biased agonist increases CD8+T Cells and natural killer cells in the tumor microenvironment; making cold tumors hot with NKTR-214
- 335A fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy
- 395A fully-automated staining assay for probing the tumor microenvironment using fluorescent multiplex immunohistochemistry
- 39A higher-affinity variant of a GD2-specific CAR significantly enhances potency in vivo and allows for a novel model of on-target off-tumor toxicity
- 77A large-scale analysis of immune cell type proportions in diverse solid tumors
- 223A model system to characterize the personalized cell immunotherapy, AGS-003, and predict functional activity in combination with PD-1 checkpoint inhibitor and sunitinib
- 185A nanoparticle based approach for optimizing T cell activation, signaling, and proliferation for adoptive immunotherapy
- 191A new target for immune checkpoint inhibition in urothelial carcinoma
- 291A non-invasive approach to assess tumor mutation load for treatment with cancer immunotherapy
- 325A novel oncolytic adenovirus expressing immunostimulatory genes that promotes an anti-tumor response
- 53A pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors
- 333A phase II multicenter trial to evaluate efficacy and safety of HF10 oncolytic virus immunotherapy and ipilimumab in patients with unresectable or metastatic melanoma
- 157A pilot/phase II study evaluating pembrolizumab plus standard-of-care chemotherapy in metastatic triple-negative breast cancer, with companion comprehensive immunological monitoring
- 59A positive control for the detection of functional CD4 T cells in human PBMC – CPI protein pool
- 151A randomized phase II study of epigenetic therapy with azacitidine and entinostat with concurrent nivolumab versus nivolumab alone in recurrent metastatic non-small cell lung cancer
- 249A specific 17-beta-hydroxywithanolide (LG-02) sensitizes cancer cells to apoptosis in response to TRAIL and toll-like receptor (TLR) ligands
- 107A test identifying advanced melanoma patients with long survival outcomes on nivolumab shows potential for selection for benefit from combination checkpoint blockade
- 43A tumor-penetrating recombinant protein anti-EGFR-iRGD enhances efficacy of antigen-specific CTL in gastric cancer in vivo
- 55A turbocharged chimeric antigen receptor against prostate cancer
- 177Activation of liver-resident myeloid cells to produce IL-27 initiates 4-1BB hepatotoxicity
- 269Adenosine regulates tumor response to radiation by hindering recruitment and activation of CD103+ DCs
- 227Adjuvant effect of anti-PD-L1 in boosting HER2-targeted T cell adoptive immunotherapy
- 45Adoptive cellular therapy (ACT) with allogeneic activated natural killer (aNK) cells in patients with advanced Merkel cell carcinoma (MCC): preliminary results of a phase II trial
- 21Adoptive transfer of ex vivo-expanded PD-1+ CD8+ and CD4+ T cells eliminates myeloma in mice
- 145AIM2CERV: a randomized phase III study of adjuvant AXAL immunotherapy following chemoradiation in patients who have high-risk locally advanced cervical cancer (HRLACC)
- 99An algorithmic approach to cancer immune profiling
- 463An Open-Label Phase I/IIa Escalating Dose Study to Evaluate Safety and T-cell Immunogenicity of PDS0101 in Subjects with Cervical Intraepithelial Neoplasia (CIN) and High-risk HPV Infection
- 125Analysis of pharmacodynamic biomarkers in the first in-human trial of GITR co-stimulation with the agonist antibody TRX-518 in advanced solid cancer patients
- 83Analytical validation of Ki67/CD8 duplex IHC assay using computational tissue analysis (cTA)
- 423Anti-CD47 monoclonal antibody SRF231 is a potent inducer of macrophage-mediated tumor cell phagocytosis and has anti-tumor activity in preclinical models
- 295Anti-leukemia immunity following STING agonist therapy requires a type I interferon-independent mechanism
- 343Anti-tumor activity of NKTR-214; a CD122-biased agonist that promotes immune cell activation in the tumor microenvironment and lymphoid tissues
- 437Arginase 2 blockage and reduction of PD-L1 expression in renal cell carcinoma
- 231Arginase inhibitor CB-1158 alleviates immunosuppression and enhances anti-tumor responses as a single agent and in combination with other immunotherapies
- 69Arming of CD56dim and CD56bright NK cells in IL-15-infused cancer patients
- 47Artificial antigen presenting cells promote expansion of tumor infiltrating lymphocytes (TILs)
- 267Assessing the potential for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors
- 61Association between microsatellite instability and clinical response across tumor types in the phase Ib KEYNOTE-012 and KEYNOTE-028 studies of pembrolizumab in PD-L1-expressing advanced solid tumors
- 135Avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: the phase III JAVELIN Renal 101 trial
- 347Bortezomib enhances expression of effector molecules in anti-tumor CD8+ lymphocytes by modulating Notch-NFκB-miR-155 crosstalk
- 49Bortezomib sensitizes cancer stem cells from solid human tumors to natural killer cell-mediated killing
- 225CA-170, a first in class oral small molecule immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer
- 215CC-122 in combination with immune checkpoint blockade synergistically activates T cells and enhances immune mediated killing of HCC cells
- 415CD103 and CD49a expression on melanoma-derived tumor infiltrating lymphocytes depend on location and a small fraction expresses memory T cell markers
- 81CD47 is overexpressed on Merkel cell carcinoma and a target for SIRPαFc therapy
- 65CD8+ T cell subsets may be associated with response to anti-CD137 agonist antibody treatment
- 355Characteristics of adjuvants for therapeutic cancer vaccines
- 71Characterization of tumor infiltrating T cell receptor (TCR) repertoire in non-muscle invasive bladder cancer (NMIBC) patients treated with Bacillus Calmette-Guérin (BCG)
- 23Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors
- 393Classification of gastric cancer based on tumor microenvironment expression of PD-L1 and CD8+ T cell infiltration
- 129Clinical responses in advanced pancreatic patients treated with bispecific antibody armed T cells (BATS)
- 239Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies
- 303Clinical significance of immune-related factors on systemic trafficking of bone marrow-derived stem cells in patients with different types of gastric neoplasms
- 111Co-expression of PD-L1 and other targetable protein and genomic markers: opportunities for combination therapy
- 25Co-expression of synthetic PD-1 fusion proteins augments HER2 CAR T cell functionality against glioblastoma
- 257Combination of Listeria-based human papillomavirus (HPV) E7 cancer vaccine (AXAL) with CD137 agonist antibody provides an effective immunotherapy for HPV-positive tumors in a mouse model
- 209Combination of a glycomimetic antagonist to E-selectin and CXCR4, GMI-1359, with an anti-PD-L1 antibody attenuates regulatory T cell infiltration and accelerates time to complete response in the murine CT26 tumor model
- 201Combination of PD-L1 blockade with oncolytic vaccines re-shapes the functional state of tumor infiltrating lymphocytes
- 443Combinatorial CD8+ and PD-L1+ cell densities correlate with response and improved survival in NSCLC patients treated with durvalumab
- 187Combined targeting of OX40 and PD-L1 metabolically reprograms T cells promote regression of large established tumors
- 13Comparison of RECIST 1.0 to RECIST 1.1 in the evaluation of adoptive cell transfer
- 417Concomitant immune tolerance in mice with tumors at two sites exhibits reciprocal tumor specificity and requires regulatory T cells
- 1Converting tumor-mediated PD-L1 inhibition into CAR T cell costimulation to potentiate adoptive T cell therapy
- 317CovIsoLink, a new enzymatic conjugation for the development of innovative antibody drug conjugates
- 15Culturing and live cell confocal imaging of ovarian cancer spheroids with monocytes and interferons
- 155CX-1158-101: a first-in-human phase I study of a small molecule inhibitor of arginase (CB-1158) as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients with solid tumors
- 293Cyclic dinucleotides activating STING are a safe and effective treatment for premalignant tumors
- 169Cytokine production by intratumorally administered activated dendritic cells correlates with survival in a phase I clinical trial
- 37Cytokines induced by pre-B leukemia progression mediates irreversible T cell dysfunction
- 351Deep profiling of tumor infiltrating immune subsets by mass cytometry
- 467Defining critical features of the immune microenvironment in melanoma
- 285Defining molecular mechanisms of resistance to tumor immunity
- 411Defining the immune microenvironment in patients with acute myeloid leukemia
- 105Development of an automated brightfield duplex IHC for simultaneous detection of PD-L1 and CD8 on lung carcinoma and tonsil FFPE tissue sections
- 363Direct Identification of Neo-epitopes in Tumor Tissue
- 397Direct oncogene-targeted cancer killing and selective tumor Treg killing through the TNFR2 receptor via dominant antibody antagonists
- 29Directing traffic: fostering chemokine receptor expression on tumor-infiltrating lymphocytes improves re-trafficking in vivo
- 253Discovery and characterization of PF-06840003, a novel brain penetrant IDO1 inhibitor
- 275Disruption of the L-arginine balance in the tumor microenvironment with a recombinant human arginase 1 (AEB1102) sensitizes cancer to immunotherapy
- 229Distinct chemokines and chemokine receptors control the trafficking of effector and regulatory cells into melanoma tumors in the setting of combined PD-1 and CTLA-4 blockade
- 369DNA vaccine with pembrolizumab elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC)
- 221Dose escalation/confirmation results of ENCORE 601, a phase Ib/II, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
- 127Dual blockade of PD-1 and CTLA-4 with bispecific antibodies promotes human T cell activation and proliferation
- 207Effect of the class I-HDAC inhibitor entinostat and the pan-HDAC inhibitor vorinostat on peripheral immune cell subsets
- 449Efficacy and Safety of Nivolumab Plus Ipilimumab in Metastatic Urothelial Carcinoma: First Results From the Phase I/II CheckMate 032 Study
- 381Efficient design method for pan-HLA multi-valent cancer vaccine
- 235Elucidating the role of CD47 in innate lymphoid cell-mediated tumor therapy
- 5Engineering 2nd generation SPEAR® T cells to overcome TGF-β-mediated immunosuppression for adoptive cell therapy
- 441Evaluation of anticancer immunity in patients with thyroid cancer with a focus towards developing effective combination immunotherapy
- 459Exercise training reduces splenic accumulation of MDSCs and delays tumor progression in a therapeutic breast cancer model
- 85Expression and prognostic significance of CD8/CD45RO tumor-infiltrating lymphocytes (TIL) and PD-L1 in cholangiocarcinoma
- 63Extensive analysis of PD-1 and CTLA-4 in HVs and GBM patients: implications for monitoring patients on checkpoint inhibitors
- 457Functional dichotomy of PI3K isoforms in CD4 T cells provides a strategy for selectively targeting regulatory T cells to enhance anti-tumor immunotherapy
- 67Gene expression markers of tumor infiltrating leukocytes
- 329Gene transfer of cytosine deaminase with Toca 511 and subsequent treatment with 5-Fluorocytosine induces anti-tumor immunity
- 211Gp96-Ig/costimulator (OX40L, ICOSL, or 4-1BBL) combination vaccine improves T cell priming and enhances immunity, memory, and tumor elimination
- 287Graphene oxide and amino functionalized graphene characterization for immunotherapy applications using new high-throughput analysis
- 297Harnessing tumor associated macrophages with a novel compound to enhance chemotherapy and checkpoint blockade in breast cancer
- 7Heterodimeric IL-15 treatment enhances tumor infiltration, persistence and effector functions of adoptively transferred tumor-specific T cells in the absence of lymphodepletion
- 115High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer
- 97High sensitivity detection of low expressing interleukins and interferons for biomarker research analysis from FFPE samples using multiplexed NGS
- 429Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk
- 379Identification and characterization of agonist human cytotoxic T cell epitopes of the human papillomavirus type 16 (HPV-16) E6/E7
- 289Identifying patient-specific neoepitopes for vaccine immunotherapy reveals rarely shared recurrent neoepitopes
- 383IL-10 blockade sensitizes ovarian cancer to anti-PD-1 antibody therapy by editing tumor-associated leukocyte populations
- 27IL-15 primes an mTOR-regulated gene-expression program to prolong anti-tumor capacity of human natural killer cells
- 41IL-2 in adoptive cell therapy – local production from an adenovirus vector instead of systemic administration results in safety and efficacy gains
- 183IL-2 signaling on tumor-infiltrating CD8+ T cells is not required for successful 4-1BB combination immunotherapy
- 95Immune activation and prolonged benefit to avelumab (anti-PD-L1) therapy in a patient with metastatic EBV+ gastric cancer
- 237Immune activation by PEGylated human IL-10 (AM0010) and anti-tumor activity in renal cancer alone and in combination with anti-PD-1
- 435Immune modulation of the cancer microenvironment for enhancing cancer immunotherapy in ovarian clear cell carcinoma
- 339Immune profiling of an elite responder following checkpoint inhibitor therapy reveals functional anti-tumor antibodies within expanded IgG lineages
- 123Immunological biomarkers correlate to survival in CAR19-treated patients
- 205Immunological impact of checkpoint blockade on dendritic cell driven T cell responses: a cautionary tale
- 233Immunomodulatory cytokine blockade in combination with CTLA-4 blockade in murine models of pancreatic cancer
- 113Immunomonitoring of patients with colorectal cancer
- 465Immunoscore as a prognostic marker in stage I-III colon cancer: Results of a SITC-led global validation study
- 341Immunoscore® Colon analytical performance
- 247Immunostimulatory and oncolytic properties of rotavirus can overcome resistance to immune checkpoint blockade therapy
- 193Impact of BTK/ITK inhibition with ibrutinib on neuroblastoma and osteosarcoma syngeneic solid tumor models
- 385Impact of immune selection pressure on epithelial cell signaling pathway activation in a syngeneic pancreatic cancer model
- 251Impact of intratumoral clonal heterogeneity on checkpoint inhibitor response
- 391Imprime PGG, a novel pathogen associated molecular pattern (PAMP) treatment elicits M1-like transcriptional profile from bone marrow-derived macrophages and tumor associated macrophages (TAMs)
- 179Imprime PGG, a soluble yeast β-glucan, is a systemically administered PAMP that activates DCs and supports T cell priming, showing synergy with cancer immunotherapies
- 31In vivo administration of immune checkpoint inhibitors prior to tumor harvest enhances the function of tumor-infiltrating T lymphocytes expanded for adoptive T cell transfer
- 353Incidence and outcomes of central nervous system metastasis in metastatic melanoma patients treated with anti-PD1 therapy
- 171Increased immune responses in melanoma patients pre-treated with CDX-301, a recombinant human Flt3 ligand, prior to vaccination with CDX-1401, a dendritic cell targeting NY-ESO-1 vaccine, in a phase II study
- 399Induction of potent and durable anti-tumor immunity by intratumoral injection of STING-activating synthetic cyclic dinucleotides
- 431Inhibition of matrix metalloproteinases by cysteamine regulates tumor invasion and metastasis in mouse models of human ovarian cancer
- 361Integrin activator 7HP349 enhances anti-CTLA-4 antibody-based cancer therapy
- 139Interim results of a phase II trial of adoptive transfer of tumor infiltrating lymphocytes in patients with metastatic uveal melanoma
- 461Intracellular trafficking of self-assembled immune signals
- 241Intrathecal AAV9.trastuzumab for both tumor prophylaxis and treatment extends survival in a murine xenograft model of HER2+ human breast cancer brain metastasis
- 357Intratumoral delivery of modified vaccinia virus Ankara expressing human Flt3L as cancer immunotherapy
- 447Intratumoral Flt3L and poly-ICLC combined with low dose radiotherapy: a novel in situ vaccine for incurable indolent lymphomas
- 337Intratumoral injection of INT230-6 induces protective T cell immunity
- 147KEYNOTE-013: an open-label, multicohort phase Ib trial of pembrolizumab in patients with advanced hematologic malignancies
- 165KEYNOTE-122: phase II study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma
- 153KEYNOTE-170: phase II study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS)
- 141KEYNOTE-177: randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma
- 163KEYNOTE-183: randomized, open-label, phase III study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in patients with refractory or relapsed/refractory multiple myeloma
- 167KEYNOTE-365: multicohort, phase Ib/II study of pembrolizumab combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
- 161KEYNOTE-426: randomized phase III study of pembrolizumab in combination with axitinib versus sunitinib monotherapy in treatment-naive advanced/metastatic renal cell carcinoma (mRCC)
- 261Live, attenuated, double-deleted Listeria monocytogenes expressing mesothelin (CRS-207) with immuno-modulatory coses of cyclophosphamide, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM)
- 315Loading of recycling MHC class I molecules with antibody-delivered viral peptides leads to efficient CD8+ T cell-mediated tumor cell killing
- 469Local convection-enhanced delivery of PD-1 blockade antibody in de novo murine model of glioblastoma
- 371Long-term follow-up of Vigil (DNA engineered bi-shRNA furin GMCSF plasmid/autologous tumor) in recurrent metastatic Ewing’s sarcoma (EWS)
- 131MCLA-117, a CLEC12AxCD3 bispecific IgG targeting a leukemic stem cell antigen, induces T cell mediated AML blast lysis
- 349Mechanisms of chitosan/IL-12 immunotherapy for the treatment of bladder cancer
- 301Melanoma cells upregulate innate immune genes in response to CTL attack
- 87Miniaturization of Luminex based multiplex cytokine assay with 96 and 384 DropArray plates
- 79miRNA a real kid for early recognition for PANcreatic adenocarcinoma (MARKER PAN study)
- 243Modulating the intra-tumor immune balance through combinatorial blockade of CSF-1R and PD-L1 enhances anti-tumor efficacy
- 299Modulation of Fcγ receptor function by HLA-G
- 213Monoclonal antibodies targeting phosphatidylserine enhance combinational activity of the immune checkpoint targeting agents LAG3 and PD-1 in murine breast tumors
- 195Multi-genome reassortant dendritic cell-tropic vector platform (ZVex®-Multi) allows flexible co-expression of multiple antigens and immune modulators for optimal induction of anti-tumor CD8+ T cell responses
- 265Multi-institution evaluation of outcomes following radiation and PD-1 inhibition
- 259Multi-kinase inhibitors for the treatment of mRCC: implications for combined therapy with AGS-003, an autologous dendritic cell immunotherapy
- 119Multiplex immunohistochemistry and image cytometry analysis for phenotyping spatial immune characteristics
- 103Multispectral immunofluorescence as a novel and complementary method of characterizing tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC)
- 245Mutational status of p53 can influence its recognition by human T cells
- 365Nanodisc neo-antigen vaccination combined with immune checkpoint blockade efficiently eliminates established tumors
- 345Nanosecond pulsed electric field treatment of tumor cell lines triggers immunogenic cell death (ICD)
- 137Neoadjuvant enoblituzumab (MGA271) in men with localized intermediate and high-risk prostate cancer – a pilot and biomarker study
- 359NKTR-214, an engineered cytokine, synergizes and improves efficacy of anti-cancer vaccination in the treatment of established murine melanoma tumors
- 175Novel tetravalent anti-GITR antibody is a potent anti-tumor agent in vivo
- 93Objective and consistent scoring of a PD-L1 complementary diagnostic with Computational Tissue Analysis (cTA™)
- 425Observation of immunobiology landscape in mucosal melanoma
- 321Oncolytic herpes simplex virus, type 1 (HSV-1) encoding GM-CSF induces HSV-1 glycoprotein B-specific T cell responses that traffic to injected and un-injected melanoma tumors
- 255Opposing effects of CTLA-4 and PD-1 blockade on follicular helper-like T cells with immunosuppressive functions
- 117Outcome disparities by sex in melanoma patients treated with anti-PD-1 therapy
- 307Overall survival and outcomes of patients treated with high dose IL-2 from the PROCLAIM registry
- 263Overcoming resistance to tyrosine kinase inhibitor by natural killer (NK) cells in non-small cell lung cancer (NSCLC) cells
- 9Partially differentiated polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocytes therapy for cancer
- 413PD-1+/OX40+ Tregs in head and neck squamous cell cancer suppress responder T cell responses
- 57PD-L1 and immune infiltrates are prognostic and differentially expressed in distinct subtypes of gastric cancer
- 409PD-L1 expressing myeloid cells limit response to CSF-1R targeted therapy
- 101PD-L1 is expressed in inflamed non-small cell lung cancer (NSCLC) specimens and its expression predicts longer patient survival, despite co-expression of other checkpoint molecules
- 331PeptiCRAd: an innovative oncolytic vaccine platform to tilt immune response from virus to tumor
- 91Persistence and turnover of therapy-induced peripheral CD4+ T cell clones in patients with metastatic melanoma upon ipilimumab therapy
- 445Pharmacodynamic gene expression changes from Talimogene Laherparepvec (T-VEC) plus Ipilimumab in a phase 1b study for metastatic melanoma
- 197Pharmacokinetics and immunogenicity of pembrolizumab when given in combination with ipilimumab: data from KEYNOTE-029
- Phase I, first-in-human, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART®) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature
- 149Phase I/Ib multicenter trial of CPI-444, an adenosine A2a receptor (A2aR) antagonist as a single agent and in combination with atezolizumab (atezo) in patients with advanced solid tumors
- 319Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical Coxsackievirus A21
- 373Phase Ib trial of two folate binding protein peptide booster vaccines (E39 and J65) in breast and ovarian cancer patients
- 133Phase II study of pembrolizumab in patients with metastatic castration-resistant prostate cancer previously treated with targeted endocrine therapy and taxane chemotherapy: KEYNOTE-199
- 143Phase III study of carboplatin-paclitaxel/nab-paclitaxel chemotherapy with or without pembrolizumab for first-line metastatic, squamous non–small cell lung carcinoma: KEYNOTE-407
- 89Phenotype, function and gene expression signatures of CD8+ T cells in patients with acute myeloid leukemia (AML)
- 199Phosphatidylserine targeting antibody in combination with checkpoint blockade and tumor radiation therapy promotes anti-cancer activity in mouse melanoma
- 35Preclinical development of tumor infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma
- 439Preclinical development of tumor-infiltrating lymphocyte therapy for pancreatic cancer
- 3Preclinical evaluation of an optimal-affinity MAGE-A4 T cell receptor for adoptive T cell therapy
- 219ProbodyTM therapeutics targeting the PD-1/L1 axis provide preclinical anti-tumor efficacy while minimizing induction of autoimmunity as single agents and in combination with CTLA-4 blockade
- 121Profiling immune cell populations and functional state with simultaneous, multiplexed detection of RNA and protein on the nCounter® platform
- 327Radiation therapy augments the effect of talimogene laherparepvec (T-VEC) on melanoma cell viability
- 313Rapid and durable complete response to atezolizumab (anti-PD-L1), with sloughing of tumor tissue through urethra, in metastatic chemotherapy-resistant urothelial cancer (UC)
- 75Rapid generation of new specificity MHC tetramers for the detection of antigen-specific T cells using a novel peptide exchange tetramer kit that allows for quantification of peptide exchange
- 427Regulation of IL-15 in the tumor microenvironment by the STING pathway
- 181Releasing the breaks: quantitative cell-based bioassays to advance individual or combination immune checkpoint immunotherapy
- 433Reprogramming of the ovarian cancer microenvironment by poly-I:C and selective TLR3 ligand, rintatolimod
- 407Role of STAT1 induced CXCL10 in tumour progression and the immune microenvironment of high-grade grade serous ovarian cancer
- 173Salvage intravesical Mycobaterium phlei cell wall-nucleic acid complex (MCNA) for BCG-unresponsive patients
- 323Selective activation of innate immune responses by the Ad11/Ad3 chimeric oncolytic group B adenovirus enadenotucirev
- 453Sequentially targeting upregulated TIM-3 and CTLA-4 does not rescue the attenuated therapeutic efficacy of combination immunotherapy with OX40 costimulation and PD-1 blockade.
- 51Shared T cell receptor sequences between HLA-A2+ patients vaccinated against a Melan-A epitope correlate with clinical benefit
- 33Simple automated manufacturing of gene engineered T cells under serum free conditions for adoptive T cell therapy
- 109Spatial distribution of CD8+ T cells predicts response to ipilimumab in malignant melanoma
- 11Stable tumor-infiltrating lymphocytes (TIL) phenotype following cryopreservation
- 401Stromal fibroblasts promote Wnt5a expression and suppress responses to anti-PD-1 antibody therapy in an autochthonous melanoma model
- 19T cell receptor gene engineered T cells targeting human papillomavirus (HPV)-16 E7 induce regression of HPV-16+ human tumors in a murine model
- 421Targeting colony stimulating factor-1 receptor (CSF-1R) with SNDX-6352, a novel anti-CSF-1R targeted antibody
- 375Targeting tumor vasculature with a DNA vaccine against endosialin (TEM1 or CD248)
- 455The combination of an IL-15/IL-15Ralpha complex (ALT-803) and anti-PD-1 mAb leads to superior anti-tumor immunity in a murine lung tumor model.
- 389The differentiation of Th17-into-Treg cells in the tumor microenvironment reveals novel targets in cancer immunotherapy
- 273The dual administration of immunotherapy is enhanced by activity-induced weight maintenance in the 4T1.2 mammary tumor model
- 311The fucosylation inhibitor 2-fluorofucose exhibits anti-tumor activity and modulates immune cell activity both in vitro and in vivo
- 271The influence of exercise and fitness on the composition of leukocytes in peripheral blood; implications for cancer immunotherapy
- 277The Wnt5a-beta-catenin pathway triggers a metabolic switch that drives indoleamine 2,3-dioxygenase activity and dendritic cell tolerization in the melanoma microenvironment: optimizing checkpoint inhibitor immunotherapy
- 367Therapeutic efficacy of cancer stem cell-vaccine in the PD-1/PD-L1 blockade
- 451Tissue factor is a novel oncotarget in triple negative breast cancer and BRAF mutated melanoma for immunotherapy using a second generation ICON (L-ICON) in monotherapy and combination therapy
- 283Transaminitis on PD-1/L1 inhibitors; the difficulties in distinguishing among progression, tumor flare and autoimmune hepatitis
- 281Treg cells utilize lactic acid to fuel immune suppression in the tumor microenvironment
- 73Tumor mutational load and T cell inflamed microenvironment are independent determinants of response to pembrolizumab
- 203Tumor necrosis factor alpha and interleukin-2 expressing adenovirus plus PD-1 blockade as a boost for T cell therapy in the context of solid tumor therapies
- 279Tumor-derived alpha-fetoprotein (tAFP) inhibits dendritic cell metabolism
- 217Ubiquitin-specific protease 6 (USP6) oncogene confers dramatic sensitivity of sarcoma cells to the immunostimulatory effects of interferon
- 309Umbelliferon-α-D-glucopyranosyl-(2I→1II)-α-Dglucopyranoside: a potential candidate affords chemoprevention against chemically-induced carcinogenesis through attenuating nuclear factor-κB
- 189Understanding the therapeutic effectiveness of alloreactive immune responses in both murine and human acute myeloid leukemia during nonegraftment cellular therapy
- 159Updated safety, efficacy, and pharmacokinetics (PK) results from the phase I study of BGB-A317, an anti- programmed death-1 (PD-1) mAb in patients with advanced solid tumors
- 403Use of experimental tumor model to characterize the effects of small-molecule CD73 inhibitors on tumor biology and immune infiltrate
- 405WISP1 stimulates melanoma cell invasion by promoting epithelial–mesenchymal transition (EMT) through both autocrine and paracrine signaling
- 202In vitro evaluation of immunotherapy protocols through a label-free impedance-based technology allows dynamic monitoring of immune response and reagent efficacy
- 322A CD47-blocking oncolytic vaccinia virus for cancer therapy
- 244A combination study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients: phase Ib KEYNOTE 200 (STORM study)
- 172A first-in-human phase I dose-escalation study of NHS-IL12 in solid tumors
- 156A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers
- 118A flexible and versatile toolbox for parallel multiplex immunohistochemical detection using recombinant epitope-tagged antibodies and monoclonal anti-tag antibodies
- 130A fusion monoclonal antibody (FmAb2) to target tumors and the immune system with a unique mechanism of action: preclinical proof-of-concept
- 290A genome-scale CRISPR screen to identify essential genes for T cell based cancer therapies
- 286A germline polymorphism associated with the T cell-inflamed tumor microenvironment in metastatic melanoma
- 128A LAG-3/PD-L1 bispecific antibody inhibits tumor growth in two syngeneic colon carcinoma models
- 336A multi-color natural killer-cell mediated cytotoxicity detection using fluorescence and direct cell imaging
- 370A multipeptide vaccine plus toll-like receptor (TLR) agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant (IFA) in melanoma patients
- 200A novel anti-human LAG-3 antibody in combination with anti-human PD-1 (REGN2810) shows enhanced anti-tumor activity in PD-1 x LAG-3 dual-humanized mice and favorable pharmacokinetic and safety profiles in cynomolgus monkeys
- 16A novel xenograft model of chimeric antigen receptor-mediated toxicity sheds light on the influence of T cell source on the severity of the toxic sequellae
- 248A phase I/II study of durvalumab alone or in combination with AXAL in recurrent/persistent or metastatic cervical or human papillomavirus (HPV)+ squamous cell cancer of the head and neck (SCCHN): preliminary phase I results
- 140A phase Ib study of intratumoral CAVATAK (coxsackievirus A21) and ipilimumab in patients with advanced melanoma
- 358A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in stage IB-IIIA breast cancer
- 186A secreted PD-L1 splice variant expressed across tumor types inhibits lymphocyte function
- 360A tumor mitochondria vaccine protects against experimental renal cell carcinoma
- 26Adoptive therapy with tumor-infiltrating lymphocytes for melanoma: interim results of a phase II single-institution study
- 72An immune-related gene expression profile delineates features of the tumor microenvironment required for clinical response to PD-1 blockade
- 326An oncolytic virus targeting tumor cell survival, desmoplasia and immune activation in pancreatic cancer
- 462Analysis of B and T cell responses in non-small cell lung cancer (NSCLC) patients enrolled in a phase II trial of cyclophosphamide with allogenic DRibble vaccine (DPV-001)
- 120Analysis of immunerelated prognostic markers in colon cancer patients randomized to surgery alone or surgery and adjuvant cytostatic treatment
- 210Antibody targeting of phosphatidylserine enhances the anti-tumor responses of ibrutinib and anti-PD-1 therapy in a mouse triple negative breast tumor model
- 94Antigen recognition avidity dependent miR-155 upregulation in melanoma tumors correlates with increased CD8+ T cell infiltrates
- 390Antigen-presenting tumor B cells associate with the phenotype of CD4 tumor infiltrating T cells in non-small cell lung cancer patients
- 106Application of a test developed for prediction of response to high dose interleukin-2 (HDIL-2) and the BDX008 test for prediction of outcomes following checkpoint inhibitors to cohorts of patients treated with HDIL-2 or nivolumab
- 116Association of non-coding repeat RNA expression with immune infiltrates
- 268ATM is essential for the radiation-induced upregulation of the immunosuppressive cytokine activin-A by breast cancer cells
- 170Augmentation of tumor infiltrating CD8+ T cells and specific response to autologous tumor antigens in a phase I trial of in situ vaccination with CCL21 gene-modified dendritic cells
- 384Axl tyrosine kinase is a key mediator of immunologic resistance after radiation therapy
- 452Beta-Adrenergic Blockade Improves the Immunotherapeutic Response to Melanoma
- 252Beyond immune checkpoint: first-in-class antibody targeting soluble NKG2D ligand sMIC for cancer immunotherapy
- 14Bioluminescent redirected lysis assay (BRLA) as an efficient potency assay to assess tumor-infiltrating lymphocytes (TILs) for immunotherapy
- 272Blockade of β-adrenergic receptor signaling enhances anti-tumor immunity while increasing the sensitivity of tumor cells to radiation therapy
- 48Blocking vasoactive intestinal peptide signaling modulates immune checkpoints and graft-versus-leukemia in allogeneic transplantation in mice
- 348Bortezomib improves adoptive T cell immunotherapy in solid tumors
- 416Cancer promotion and immune tolerance via cancer cell - intrinsic surface expression of GARP
- 306Cancer testis antigens, immunotherapeutic target antigens in triple negative breast cancer
- 4Case report: specific peptide enhanced affinity receptor T cells (SPEAR® T cells) demonstrate long-term persistence and both in vivo and ex vivo tumoricidal activity
- 324CD40L-armed oncolytic LOAd viruses control growth of CD40+ T24 bladder cancer via both oncolysis and CD40-mediated apoptosis
- 410CD56+ cell infiltration correlates with a worse prognosis in cholangiocarcinoma
- 404CD8α+ dendritic cells regulate leukemia antigen-specific CD8+ T cell tolerance
- 104Changes in uveal melanoma immune infiltrate in response to checkpoint blockade
- 188Characterization of infiltrating lymphocytes in benign, malignant, and healthy prostate tissue
- 438Chemoimmunotherapy with Cyclophosphamide and tumor reactive CD4+T cells leads to destruction of tumor vasculature and eventual tumor eradication
- 284Cognate pairing of human T cell receptor alpha and beta V-regions from single cells
- 226Combination of local immunotoxins with CTLA-4 blockade eradicates murine tumors by promoting anti-cancer immunity
- 222Combinatorial reprograming of chemokine environment in colorectal and ovarian cancer patients to promote intratumoral CTL infiltration
- 266Combined blockade of CTLA-4 and CD47 with tumor irradiation extends survival in melanoma
- 228Combining IL-6 blockade with novel targeted therapeutics in pancreatic cancer
- 84Combining the best of both worlds: immune profiling the tumor microenvironment with RNA and protein biomarkers by fluorescence multiplex RNA in situ hybridization and immunohistochemistry
- 450Computational identification, functional characterization and antibody blockade of a new immune checkpoint in the TIGIT family of interacting molecules
- 182Costimulatory T cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and tumor-localized CD8+ T cell expansion in a humanized mouse model
- 218CPI-444: a potent and selective inhibitor of adenosine 2A receptor (A2AR) induces anti-tumor responses alone and in combination with anti-PD-L1.
- 288Curated GEO dataset collection for discovery and validation of breast cancer immune phenotypes
- 166CX-839-004: a phase I/II study of the safety, pharmacokinetics, and pharmacodynamics of the glutaminase inhibitor CB-839 combined with nivolumab in patients with renal cell carcinoma, melanoma, and non-small cell lung cancer
- 340Cytokine profile of sipuleucel-T in differentiating reactivation of latent immunity from de novo immune responses
- 442Development and Clinical Translation of 89Zr-Df-IAB22M2C for Detecting CD8+ T Cells for Immunotherapy Applications
- 366Development of personalized, live, attenuated double-deleted Listeria monocytogenes (pLADD) immunotherapy targeting tumor-specific neoantigens to treat cancer
- 430Direct visualization of tumor immune evasion against CD8+ effector T cells using intra-vital microscopy
- 90Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy
- 174DNA methylation changes in CD8+ T cells following 4-1BB costimulation
- 154Dose-seeking and efficacy study of anti-PD-1 therapy with pembrolizumab (P) combined with BRAF inhibitor (BRAFi) therapy with vemurafenib (V) for therapy of advanced melanoma
- 184Dual function STAT3 inhibitor (CpG-STAT3ASO) generates systemic antitumor immune responses resulting in eradication of bone-localized prostate tumors in mice
- 464Effects of TLR7 agonist imiquimod combined with local radiotherapy on the tumor microenvironment in women with metastatic breast cancer in a prospective trial
- 318Efficacy of variable dose of gallic acid to combat chemically induced hepatocarcinogenesis by altering the hepatic proinflammatory cytokines and oxidative stress
- 396EGFR/JAK2 inhibition downregulates immunosuppressive cytokine secretion in head and neck cancer
- 254Enhanced anti-tumor effect of combination therapy with NHS-muIL-12 and anti-PD-L1 antibody (avelumab) in a preclinical cancer model
- 102Enhanced vaccine-induced T cell responses observed with ipilimumab (anti-CTLA-4) treatment in a nonhuman primate pharmacodynamic model
- 220Enhancement of target expression on breast tumors via hormone receptor antagonism: a novel strategy for enhancing immunotherapeutic efficacy
- 22Entinostat sensitized osteosarcoma cells for cytotoxic effect of natural killer cells
- 198Establishing a model for successful immunotherapy with T-Vec combined with BRAF inhibition and anti-PD-1 in genetically engineered murine melanoma
- 40Evaluating the potential of Müllerian inhibiting substance type II receptor (MISIIR) as a target for CAR T cell therapy against ovarian cancer
- 114Evaluation of AP-1 signaling by interleukin-13 in human glioblastoma cells
- 176Evaluation of immune cell infiltrates in non-small cell lung cancer as a potential comprehensive prognosticator
- 350Extracellular vesicles as carriers for the delivery of immunotherapeutic oligonucleotides
- 246Fc gamma receptor IV mediated depletion of tumor infiltrating regulatory T cells by anti-CTLA-4 antibody is promoted by TLR1/2 agonist and hence its efficacy in combination treatment of melanoma
- 168Final statistical analysis of a pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma
- 190First-in-class orally bioavailable checkpoint inhibitors targeting single and multiple immune inhibitory pathways
- 338Fluorine-19 nuclear magnetic resonance (NMR) to track and quantify human transgenic T cell biodistribution in murine studies of glioblastoma immunotherapy
- 58Four color T and B cell ELISPOT assays for simultaneous detection of analytes
- 28Functional characterization of CD4+ and CD8+ CD19 chimeric antigen receptor T cells
- 180Functional characterization of CDX-1140, a novel CD40 antibody agonist for cancer immunotherapy
- 374Genome-scale neoantigen screening using ATLAS™ prioritizes candidates for immunotherapy in a non-small cell lung cancer patient
- 356Glycosylated and methylated peptides as neoantigens in leukaemia
- 376Hafnium oxide nanoparticle, a radiation enhancer for in situ cancer vaccine
- 20haNK, a cytotoxic human high affinity natural killer cell line, exerts enhanced ADCC mediated by avelumab (an anti-PD-L1 antibody) against multiple human tumor cell lines
- 354Heterologous boosts with an adenoviral vector following a dendritic cell-tropic ZVex® prime generates robust antigen-specific T cell responses and enhanced anti-tumor protection
- 444High Dose Interleukin 2 (HD IL-2) Select Trial in Melanoma: A tissue and blood collection protocol to identify predictive biomarkers of benefit to HD IL-2 in patients with advanced melanoma.
- 92High frequencies of PD-1+CD8+ T cells are correlated with PD-L1+ circulating tumor cells (CTC) and have predictive/prognostic value in non-small cell lung cancer (NSCLC) patients
- 36Human natural killer cells engineered to express a chimeric NK activating receptor have activity against highly suppressive cells of the solid tumor microenvironment
- 270β-adrenergic signaling induced by cool housing temperatures mediates immune suppression and impairs the efficacy of anti-PD-1 checkpoint blockade immunotherapy in laboratory mice
- 70Identification of a novel subset of tumor-resident human CD8+ T cells, marked by dual expression of CD103 and CD39
- 38Identification of a recurrent high-affinity MHC class I restricted neoepitope in neuroblastoma using ProTECT
- 302Identification of T cell receptors targeting the intestinal self-antigen and colorectal cancer target GUCY2C by next-generation sequencing
- 204IMM-101 primes for increased complete responses following checkpoint inhibitors in metastatic melanoma; 3 case reports
- 86Immune cell based assay with suspension cells and wall-less DropArray plate
- 386Immune cell spatial analysis on FoxP3 and CD8 positive IHC stained T cells within the tumor microenvironment
- 468Immune profiling via multiplexed immunofluorescence shows that Imprime based anti-cancer efficacy involves profound changes in macrophage polarization, type 1 IFN signaling and the formation of immune cell clusters
- 96Immune-enriched NSCLC biopsy tissue microarrays demonstrate that proliferating and checkpoint expressing TIL correlate with positive outcome
- 44Immunodominance of cancer neoantigen and cancer-germline antigen T cell reactivities in successful immunotherapy of virally-induced epithelial cancer
- 112ImmunoMap: a novel bioinformatics tool for analysis of T cell receptor repertoire data in model systems and clinical settings
- 242Immunotherapy of head and neck squamous cell cancers with synthetic TLR agonists and checkpoint inhibitors in preclinical models
- 368Immunotherapy with INO-3112 (plasmids encoding HPV16 and HPV18 E6/E7 antigens and IL-12) induces immune responses in peripheral blood and tumor tissue in patients with HPV associated head and neck squamous cell carcinoma (HNSCCa)
- 234Improvement of a therapeutic cancer vaccine in mice with the addition of a GITR-ligand fusion protein
- 78Increased antibody and T cell responses to neoepitope site peptides following combination immunotherapy with a complex cell-derived cancer vaccine
- 124Increased STAT3 signaling and decreased suppressive function of regulatory T cells are biomarkers of positive patient outcome to nivolumab therapy
- 6Inducible MyD88/CD40 (iMC) costimulation drives ligand-dependent tumor eradication by CD123-specific chimeric antigen receptor T cells
- 294Inflammatory activation via PKC-Syk pathway in macrophages lacking CD47-SIRPα restraint initiates potent phagocytosis toward cancer
- 402Inhibitors of B cell activation reduce tumor growth and attenuate pro-tumorigenic phenotype of tumor immune infiltrates in a syngeneic mouse model of ovarian cancer
- 238Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies
- 392Integrated genomics approach of modeling tumors to assess their sensitivity to immune-mediated elimination
- 298Interferon production and immunity elicited by a constitutively active form of interferon-beta promoter stimulator-1 (IPS-1)
- 328Interim results of the CAPRA clinical trial: CAVATAK and pemrolizumab in advanced melanoma
- 300Intestinal microbiota and relapse after hematopoietic-cell transplantation
- 264Intralesional injection with Rose Bengal and systemic chemotherapy induces anti-tumor immunity in a murine model of pancreatic cancer
- 362Intramuscular anti-HER2 antibody gene transfer as an alternative to conventional antibody protein therapy: a pre-clinical proof of concept study in breast cancer
- 250Intratumoral administration of the TLR7/8 agonist MEDI9197 inhibits tumor growth and modulates the tumor microenvironment
- 364Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers - a phase I/II study in patients with advanced hepatocellular carcinoma
- 406Jak/STAT signaling as a mediator of immune suppression from pancreatic stellate cells in vitro and caerulein-induced pancreatitis in vivo
- Keynote-045: open-label, phase III study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer
- 146KEYNOTE-057: phase II study of pembrolizumab in patients with Bacillus Calmette Guérin (BCG)–unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC)
- 134KEYNOTE-155: phase Ib study of pembrolizumab in combination with dinaciclib in patients with hematologic malignancies
- 164KEYNOTE-185: randomized, open-label, phase III study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with newly diagnosed and treatment-naïve multiple myeloma (MM)
- 132KEYNOTE-361: randomized phase III study of pembrolizumab with or without chemotherapy versus chemotherapy alone in advanced urothelial carcinoma
- 152KEYNOTE-427: phase II study of pembrolizumab in patients with locally advanced/metastatic renal cell carcinoma (mRCC)
- 2Lack of moesin improves adoptive T cell therapy by potentiating anti-tumor functions
- 426Leukocyte chemoattractant chemerin upregulates PTEN activity in human tumors via CMKLR1
- 380Liposome-encapsulated doxorubicin is a promising adjuvant to increase the efficacy of mTERT DNA-vaccine
- 418Local but not distant viral infection improves cancer outcomes: implications for cancer immunotherapy
- 224Local intratumoral treatment with low-dose CD40 and TLR4 agonists overcomes resistance to PD-1 blockade to control tumors systemically
- 46Low dose conditioning chemotherapy and CD19-directed CAR T cells may elicit distinct immune programs associated with clinical responses
- 414Lymphatic vessels as biomarkers of in situ immunity in melanoma
- 282Management of immune-mediated diarrhea and the impact of infliximab on outcome
- 60Maximizing odds for detecting a positive T cell response by ELISPOT
- 278Metformin treatment synergizes with PD-1 blockade therapy by reducing tumor hypoxia
- 88Miniaturization of Singulex/Erenna based multiplex cytokine assay with wall-less DropArray 96 plates
- 280Mitochondrial biogenesis is repressed in tumor-infiltrating CD8+ T cells resulting in metabolic insufficiency and T cell dysfunction
- 212Modulation of antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by the anti-PD-L1 antibody avelumab on human lung and prostate carcinoma cell lines using the HDAC inhibitors vorinostat and entinostat
- 400Modulation of NK cell exhaustion in metastatic melanoma tumors
- 394Molecular profiling of tumor microenvironment for biomarker discovery
- 346Monitoring the changes in tumor-specific TILs during immunotherapy
- 126Multiple bispecific checkpoint combinations enhance T cell activity
- 260Multiple tumor antigen-activated T cell therapy elicits Individual and dynamic T cell responses in patients with hepatocellular carcinoma
- 274Multi-species assessment of the impact of aging and obesity on T cell exhaustion
- 276NAD-Sirt1 axis is central to the unique immuno-metabolic phenotype of Th1/17 hybrid cells in regulating its enhanced anti-tumor potential
- 420Nano-Pulse Electro-Signaling treatment of murine tumors significantly reduces the percentage of regulatory T-cells in the treated tumor
- 344Nanosecond pulsed electric field treatment of murine melanomas initiates an immune response and inhibits metastasis
- 422Neuropilin-1-deficient regulatory T cell-derived interferon-γ drives infectious instability and tumor clearance
- 352Neutrophil count predicts survival in patients on ipilimumab with radiation
- 80Neutrophil lymphocyte ratio as a biomarker predictive of clinical outcome with nivolumab therapy in RCC
- 82Neutrophil-to-lymphocyte ratio (NLR) as a predictive biomarker of induction chemotherapy for stage IVA or IVB nasopharyngeal carcinoma (NPC) patients – a post-hoc analysis on Taiwan cooperative oncology group (TCOG) 1303 study
- 74Next generation techniques for biomarker development, validation and implementation reveal the importance of non-coding RNAs in predicting response to immunotherapy
- 388NF-kB p50 promotes the suppressive M2 phenotype of tumor-associated macrophages in a mouse model of glioma
- 196NK, T cells and IFN-gamma are required for the anti-tumor efficacy of combination-treatment with NKG2A and PD1/PDL1 checkpoint inhibitors in preclinical models
- 342NKTR-255: an IL-15-based therapeutic with optimized biological activity and anti-tumor efficacy
- 310Novel and shared neoantigen derived from histone 3 variant H3.3 K27M mutation – characterization of the epitope and cloning of a specific T cell receptor for glioma T cell therapy
- 454Novel IL-2/mAb complexes mediate potent anti-tumor immunity which is augmented with anti-PD-1 mAb therapy.
- 64Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
- 296Opposing roles of natural killer cell subsets in a mouse model of acute myeloid leukemia and hematopoietic stem cell transplant
- 100PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: correlation with tumor infiltrating immune cells and clinical outcome
- 458Pembrolizumab in combination with chemoradiotherapy (CRT) for locally-advanced squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis (ISA)
- 10Peptide vaccine enhances antitumor effect of adoptive cell transfer using genetically engineered T cells
- 378Peptide vaccines/IL2 complex combination expands high quality endogenous T cell responses that eradicate tumors
- 54Pharmacologic rejuvenation of exhausted T cells to improve adoptive TIL therapy
- 446Phase I study of alpha-tocopherlyoxyacetic acid in patients with advanced cancer: Immune response and pharmacokinetics results
- 470Phase I, first-in-human, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART®) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature
- 142Phase Ia/Ib trial investigating the CSF-1R inhibitor LY3022855 in combination with durvalumab (MEDI4736) or tremelimumab in patients with advanced solid malignancies
- 262Phase Ib trial of RNActive® cancer vaccine BI1361849 (CV9202) and local radiotherapy in stage IV non-small cell lung cancer (NSCLC) patients with disease control after 1st-line therapy: updated clinical results and immune responses
- 334Phase II CALM extension study: intratumoral CAVATAK™ increases immune-cell infiltrates and up-regulates immune-checkpoint molecules in the microenvironment of lesions from advanced melanoma patients
- 466Phase II Study of Intratumoral plasmid Interleukin 12 (pIL-12) with Electroporation in Combination with Pembrolizumab in Stage III/IV Melanoma Patients with Low Tumor Infiltrating Lymphocytes
- 312Phosphopeptides as novel tumor antigens in colorectal cancer
- 314Preclinical immunological and anti-tumor data of the new enantiomeric TLR9 agonist EnanDIM
- 332Pre-existing immunity to oncolytic virus potentiates its therapeutic efficacy.
- 408Pre-implantation factor (PIF) – blocks proliferation and enhances tumor footprint in cultured human metastatic melanoma lymph nodes – translational aspects
- 456Preliminary efficacy from a phase 1/2 study of the natural killer cell–targeted antibody, lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck
- 144Preliminary manufacturing, safety, and immune monitoring results of an allogeneic tumor lysate-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
- 448Preliminary safety and efficacy data for radiotherapy and PD-L1 checkpoint blockade in metastatic non-small cell lung cancer: Is timing everything?
- 160Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer
- 292Profiling abscopal regression in a pediatric fibrosarcoma with a novel EML4-NTRK3 fusion using immunogenomics and high-dimensional histopathology
- 30Provision of inducible MyD88 and CD40 co-stimulation in CAR T cells results in potent antitumor activity in preclinical solid tumor models
- 304Quantification of natural killer cell-mediated cytotoxicity using Celigo imaging cytometry
- 68Quantitative real-time PCR based diagnostic to assess NKT cell function in breast cancer patients
- 138Radiotherapy enhances natural killer cell homing and function in canine bone and soft tissue sarcoma
- 194Rational combinations of intratumoral T cell and myeloid agonists mobilize abscopal responses in prostate cancer
- 216Reactivating the anti-tumor immune response by targeting innate and adaptive immunity in a phase I/II study of intratumoral IMO-2125 in combination with systemic ipilimumab in patients with anti-PD-1 refractory metastatic melanoma
- 12Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from human breast cancer metastases
- 32Redirecting gene-engineered T cells through covalent attachment of targeting ligands to a universal immune receptor
- 66Regulation of PD-L1 expression in melanoma and immune cells
- 24Regulation of T cell sensitivity by TCR-proximal signaling components during anti-melanoma responses
- 428Regulatory T cell derived inhibitory cytokines IL35 and IL10 promote T cell dysfunction in the tumor microenvironment
- 108Reproducibility of automated and semi-automated seven-color immunofluorescence staining with tyramide signal amplification
- 236Restoration of antitumor effectiveness of PD-1 inhibition in immunotherapy-resistant “cold” tumors by combinatorial treatment enhancing the numbers of tumor-specific CTLs in tumor tissues
- 178Restoration of tumor-infiltrating lymphocyte function by panobinostat and tumor eradication with the combination of panobinostat and PD-1 blockade
- 232Revealing how adoptive T cell transfer into lymphodepleted host and checkpoint blockade therapy work together to treat blood cancers
- 150SEA-CD40 is a CD40 agonist with early evidence of pharmacodynamic and antitumor activity: preliminary results from a phase I study in advanced solid malignancies
- 76Selection of indications for JTX-2011 ICONIC clinical trial
- 424Selective small molecule inhibitors of CD73 promote human CD8+ T cell activation and positively impact tumor growth and immune parameters in experimental tumor models
- 208Shifting the balance of tumor-mediated immune suppression and augmenting immunotherapy with antibody blockade of semaphorin 4D to facilitate immune-mediated tumor rejection
- 122Spatially-resolved, multiplexed digital characterization of protein and mRNA abundance in FFPE tissue sections: application to immuno-oncology
- 42Successful expansion and characterization of tumor infiltrating lymphocytes (TILs) from non-melanoma tumors
- 440Synthetic biology approaches to enhance adoptive cell therapy safety and precision
- 460Systemic Immunotherapeutic Efficacy of an Immunocytokine, NHS-muIL12, in a Superficial Murine Orthotopic Bladder Cancer Model
- 18T cell antigen couplers (TAC) demonstrate strong effectivity against solid tumors with no measurable toxicities, demonstrating an enhanced therapeutic index
- 158T cell therapy for patients with advanced ovarian cancer: a pilot study in progress
- 136T cell therapy in combination with vemurafenib in BRAF mutated metastatic melanoma patients
- 52T cells redirected to TEM8 have antitumor activity but induce ‘on target/off cancer toxicity’ in preclinical models
- 50Targeted NK cells display potent activity against glioblastoma and induce protective antitumor immunity
- 436Targeting fibroblast activation protein in combination with radiation
- 206Targeting the PD-1/PD-L1 signaling pathway for the treatment of OS lung metastasis
- 230Targeting tumor glutamine metabolism with CB-839 enhances the efficacy of immune checkpoint inhibitors
- 308Tetrahydrouridine and decitabine combination for p53-independent cytoreduction and immune-priming of NSCLC in vivo
- 240The effects of combination treatment of IMM-101, a heat-killed whole cell preparation of Mycobacterium obuense (NCTC 13365) with checkpoint inhibitors in pre-clinical models
- 214The immunoreceptor TIGIT regulates anti-tumor immunity
- 320The oncolytic effect of talimogene laherparepvec (T-VEC) can be augmented by MEK inhibition in melanoma cell lines
- 192Therapeutic T cell activation using engineered variant IgSF domains
- 412Tim-3+CD4+CD25hiFOXP3+ regulatory T cells underlies enhanced suppressive function in HNSCC patients
- 434TLR9 expression in prostate cancer cells results in leukemia inhibitory factor (LIF)-mediated accumulation of pSTAT3+ myeloid-derived suppressor cells
- 162Translational studies identify ICOS agonist antibody JTX-2011 as a novel immunotherapy option for HNSCC patients
- 316Treatment of tumor cells with mirvetuximab soravtansine, a FRalpha-targeting antibody-drug conjugate (ADC), activates monocytes through Fc-FcgammaR interaction and immunogenic cell death
- 148Trials in progress: a phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC
- 330T-StealthTM technology mitigates antagonism between oncolytic viruses and the immune system through viral evasion of anti-viral T cells
- 34Tumor Infiltrating lymphocytes from soft tissue sarcoma have tumor-specific function
- 110Tumor-associated macrophages as a prognostic marker for prostate cancer progression
- 258Tumor-resident T cells survive and mediate the antitumoral effects in a murine model of cancer therapy with localized ionizing radiation
- 372Vaccination of advanced or relapsed prostate cancer patients with WT1 peptide-pulsed dendritic cells induces immunological and clinical responses
- 98Validation of a custom RNA-Seq approach to cancer immune profiling
- 432Validation of FGFR3 activation in non-T cell-inflamed bladder cancer
- 62Whole-blood RNA transcript-based signatures predict pre- and post-treatment response in two large independent clinical studies of patients with advanced melanoma treated with tremelimumab
- 256WT1 peptide vaccine in montanide or poly-ICLC triggers different immune responses in patients with myeloid leukemia
